ChemoCentryx Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ChemoCentryx stock.
View analyst ratings for ChemoCentryx or view top-rated stocks.

Wall Street analysts have given ChemoCentryx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ChemoCentryx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for ChemoCentryx.

ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings results on Sunday, August, 8th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.01. The biopharmaceutical company earned $1.81 million during the quarter, compared to analyst estimates of $4.85 million. ChemoCentryx had a negative trailing twelve-month return on equity of 33.17% and a negative net margin of 568.54%. The business's revenue was down 96.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.29 EPS.
View ChemoCentryx's earnings history.

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CCXI stock has decreased by 60.3% and is now trading at $16.48.
View which stocks have been most impacted by COVID-19.

8 brokers have issued twelve-month target prices for ChemoCentryx's shares. Their forecasts range from $17.00 to $70.00. On average, they expect ChemoCentryx's stock price to reach $37.88 in the next twelve months. This suggests a possible upside of 129.8% from the stock's current price.
View analysts' price targets for ChemoCentryx or view top-rated stocks among Wall Street analysts.

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of CCXI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR).

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx's stock is owned by many different retail and institutional investors. Top institutional investors include Jefferies Group LLC (0.00%), FMR LLC (14.97%), Vanguard Group Inc. (6.95%), State Street Corp (6.76%), BlackRock Inc. (6.68%) and RA Capital Management L.P. (5.00%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends for ChemoCentryx.

CCXI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, International Biotechnology Trust PLC, Bank of America Corp DE, California Public Employees Retirement System, Tekla Capital Management LLC, RA Capital Management L.P., and Alliancebernstein L.P.. Company insiders that have sold ChemoCentryx company stock in the last year include Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Thomas A Edwards, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx or view top insider-selling stocks.

CCXI stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, State Street Corp, Susquehanna International Group LLP, Ikarian Capital LLC, Parallax Volatility Advisers L.P., Simplex Trading LLC, Squarepoint Ops LLC, and Citigroup Inc..
View insider buying and selling activity for ChemoCentryx or or view top insider-buying stocks.

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CCXI stock can currently be purchased for approximately $16.48.

ChemoCentryx has a market capitalization of $1.15 billion and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55,360,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

ChemoCentryx employs 133 workers across the globe.

The official website for ChemoCentryx is www.chemocentryx.com.

ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at (650) 210-2900 or via email at [email protected].